1. Home
  2. DUO vs CMMB Comparison

DUO vs CMMB Comparison

Compare DUO & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DUO

Fangdd Network Group Ltd.

HOLD

Current Price

$0.58

Market Cap

24.6M

Sector

Finance

ML Signal

HOLD

Logo Chemomab Therapeutics Ltd.

CMMB

Chemomab Therapeutics Ltd.

N/A

Current Price

$2.73

Market Cap

19.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DUO
CMMB
Founded
2011
2004
Country
China
Israel
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.6M
19.9M
IPO Year
2018
2023

Fundamental Metrics

Financial Performance
Metric
DUO
CMMB
Price
$0.58
$2.73
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
2.3M
98.7K
Earning Date
05-12-2026
05-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
101.67
EPS
N/A
0.04
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$68.00
Revenue Growth
N/A
N/A
52 Week Low
$0.54
$1.35
52 Week High
$5.34
$3.55

Technical Indicators

Market Signals
Indicator
DUO
CMMB
Relative Strength Index (RSI) 43.89 81.92
Support Level $0.58 $1.47
Resistance Level $0.70 $2.80
Average True Range (ATR) 0.10 0.19
MACD 0.01 0.07
Stochastic Oscillator 0.11 77.42

Price Performance

Historical Comparison
DUO
CMMB

About DUO Fangdd Network Group Ltd.

Fangdd Network Group Ltd is an investment holding company. It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China. All revenues of the Group are derived from the PRC.

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.

Share on Social Networks: